Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.

Joseph L Witztum,Daniel Gaudet,Marcello Arca,Alan Jones,Handrean Soran,Ioanna Gouni-Berthold,Erik S G Stroes,Veronica J Alexander,Richard Jones,Lynnetta Watts,Shuting Xia,Sotirios Tsimikas

Journal of clinical lipidology（2023）

引用 4|浏览18

暂无评分

摘要

Extended open-label treatment with volanesorsen in patients with FCS resulted in sustained reductions of plasma TG levels and safety consistent with the index studies.

查看译文

关键词

Antisense oligonucleotides,Familial chylomicronemia,Hyperlipoproteinemia type I,Triglycerides,Volanesorsen

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要